Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) reported a fourth-quarter loss that was narrower than analysts anticipated, bolstered by a significant cash injection and clinical progress in its high-priority obesity and oncology programs.
The Norwood, Massachusetts-based biotech narrowed its adjusted quarterly loss to $1.25 per share, outperforming the $1.78 per share loss expected by Wall Street, even as it ramped up research spending for its lead assets.
Corbus reported a net loss of $20.6 million for the quarter ended December 31, 2025, compared to a loss of $9.5 million in the prior-year period.
The widening loss reflects an intentional $9.4 million increase in operating expenses, primarily driven by accelerated clinical development for its next-generation antibody-drug conjugate (ADC), CRB-701, and its oral obesity candidate, CRB-913.
For the full year 2025, the company reported a net loss of $78.5 million, or $5.90 per share.
Despite the year-end deficit, Corbus enters 2026 with a substantially bolstered balance sheet.
Following a $75 million public offering in the fourth quarter, the company ended the year with $163.3 million in cash and investments.